Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

GTAEXS617 · REC-617

Small molecule · Inhibitor of cyclin-dependent kinase 7 (CDK7) · developed by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals

Phase 1/2 Most advanced trial
RXRX Developer
1 Registered trials

What is GTAEXS617?

GTAEXS617 (REC-617) is an orally bioavailable, non-covalent, reversible inhibitor of cyclin-dependent kinase 7 (CDK7). By blocking CDK7, it prevents phosphorylation of the RNA polymerase II carboxy-terminal domain and of cell cycle kinases CDK1, 2, 4 and 6. It is being studied in head and neck squamous cell carcinoma, pancreatic adenocarcinoma, non-small cell lung cancer, ovarian cancer, and breast and triple negative breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
REC-617
Drug type
Small molecule
Targets
cyclin-dependent kinase 7 (CDK7)
Mechanism
Inhibitor of cyclin-dependent kinase 7 (CDK7)
Pathways
RNA polymerase II CTD phosphorylation, transcriptional regulation, cell cycle progression (CDK1, CDK2, CDK4, CDK6 phosphorylation), apoptosis, DNA damage repair
Therapy area
Oncology
Developer
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. (RXRX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05985655 Phase 1/2 Head and Neck Squamous Cell Carcinoma (HNSCC) Recruiting RXRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Pancreatic AdenocarcinomaTriple Negative Breast Cancer (TNBC)

Other drugs acting on CDK7

More from Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the RXRX page.

Follow RXRX, the company behind GTAEXS617

See RXRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RXRX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.